Tianjin Kanghong Pharmaceutical Technology Development

Tianjin Kanghong Pharmaceutical Technology Development is a subsidiary of the Chengdu Kanghong Pharmaceutical Group, a leading Chinese pharmaceutical company focused on the research, development, and commercialization of innovative drugs. The Tianjin entity serves as a key research and development hub, contributing to the group's portfolio in ophthalmology, central nervous system disorders, and digestive system health. Its parent company is best known for developing Conbercept, a blockbuster anti-VEGF fusion protein used to treat various retinal diseases. The company integrates modern biotechnology with traditional Chinese medicine expertise to address significant unmet medical needs. Tianjin Kanghong plays a vital role in the group's strategy to expand its innovative pipeline and maintain high manufacturing standards within the Chinese market.